Updates
** Drug developer Arvinas' ARVN.O shares fall 50.3% to $8.73, hitting all-time low
** Pfizer PFE.N and ARVN say their experimental breast cancer treatment failed to delay progression of the disease in a broader group of patients in a late-stage trial
** Pfizer's PFE.N shares fall 1.6% to $26.22
** Arvinas says vepdegestrant failed to show statistically significant improvements in the intent-to-treat $(ITT)$ population
** The ITT population represents a substantially larger group of patients, which could have led to a ~$4 bln in additional revenue upside - Brokerage BMO Capital Markets
** But the drug helped improve progression-free survival in a subgroup of patients with a genetic form of the most common type of breast cancer
** As of last close, ARVN down 62.7% in past 12 months
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.